In a 33-year-old woman with hirsutism, what is the appropriate diagnostic workup and treatment options?

Workup and Treatment for Hirsutism in a 33-Year-Old Woman

For a 33-year-old woman with hirsutism, begin by assessing severity using the Ferriman-Gallwey score and checking for red flags; if moderate-to-severe hirsutism (score >15) or any concerning features are present, measure early morning total testosterone on cycle days 4-10, then pursue additional endocrine workup if elevated. 1

Initial Clinical Assessment

Determine Hirsutism Severity

• Mild hirsutism: Ferriman-Gallwey score 8-15
• Moderate-to-severe hirsutism: Score >15
• Note that even mild hirsutism in Asian women may indicate androgen excess due to ethnic differences in normal hair distribution 1

Screen for Red Flags Requiring Immediate Workup

Regardless of severity, test for androgen excess if ANY of the following are present 1:

• Sudden onset or rapid progression of hair growth
• Virilization signs: clitoromegaly, deepening voice, increased muscularity, male pattern baldness
• Abdominal or pelvic mass
• Menstrual irregularity or infertility
• Associated features: acne, seborrhea, central obesity, acanthosis nigricans

Medication History

Discontinue if possible 1:

• Anabolic or androgenic steroids (consider in athletes, patients with endometriosis)
• Valproic acid (the only anticonvulsant that raises testosterone)
• Danazol

Laboratory Workup Algorithm

For Isolated Mild Hirsutism (Score 8-15) with Regular Menses

Do NOT test for androgens - the likelihood of finding a disorder that changes management is low 1. Proceed directly to treatment with cosmetic measures or oral contraceptives.

For Moderate-to-Severe Hirsutism OR Mild Hirsutism with Risk Factors

Initial test: Early morning total testosterone on menstrual cycle days 4-10 1

If testosterone is normal but risk factors persist or hirsutism worsens: Recheck with both total AND free testosterone in a specialty laboratory 1

If testosterone is elevated, obtain the following to exclude serious causes 1:

• Pregnancy test (if amenorrheic)
• Pelvic ultrasound (to detect ovarian neoplasm or polycystic ovaries)
• DHEAS (dehydroepiandrosterone sulfate) to assess adrenal androgen production
• Early morning 17-hydroxyprogesterone (to exclude nonclassic congenital adrenal hyperplasia)
• Prolactin level (to exclude hyperprolactinemia)
• Additional testing only if clinically indicated: Cushing's syndrome screening, thyroid function, acromegaly evaluation

Critical threshold: Testosterone >200 ng/dL is highly suggestive of androgen-secreting tumor requiring imaging 2

Treatment Approach

First-Line Pharmacological Therapy

For the majority of women with patient-important hirsutism, start with oral contraceptive pills (OCPs) 1. This is the preferred monotherapy because:

• Antiandrogen monotherapy is contraindicated without adequate contraception due to teratogenic potential 1
• OCPs suppress ovarian androgen production effectively

OCP selection: Use preparations containing 20-35 µg ethinyl estradiol. While theoretically preferable to avoid levonorgestrel-containing OCPs in favor of those with low-androgenic progestins (norgestimate, desogestrel) or antiandrogenic progestins (drospirenone), clinical trial data showing superiority are limited 1

Adding Antiandrogen Therapy

If hirsutism remains patient-important after 6 months of OCP monotherapy, add an antiandrogen 1:

Antiandrogen options and dosing 1:

• Spironolactone: 100-200 mg/day in divided doses (twice daily)
• Finasteride: 2.5-5 mg/day
• Cyproterone acetate (CPA): 50-100 mg/day on cycle days 5-15 with ethinyl estradiol 20-35 µg on days 5-25 (not available in United States)

Avoid flutamide due to hepatotoxicity risk 1

Therapies NOT Recommended

• Insulin-lowering drugs: Not effective for hirsutism treatment 1
• Glucocorticoids: Only use for nonclassic congenital adrenal hyperplasia with suboptimal response to OCPs/antiandrogens 1
• GnRH agonists: Reserve only for severe hyperandrogenemia (e.g., ovarian hyperthecosis) unresponsive to OCPs and antiandrogens 1
• Topical antiandrogens: Ineffective 1

Hair Removal Methods

For women desiring additional cosmetic benefit or as alternative to pharmacotherapy:

• Photoepilation/laser therapy is the preferred direct hair removal method 1
• Can add eflornithine cream for more rapid initial response
• Traditional methods (shaving, plucking, waxing, electrolysis) remain options

Treatment Timeline and Expectations

Allow at least 6 months before changing dose, switching medications, or adding therapy 1. Hair growth cycles are slow, and pharmacological effects take time to manifest.

Common Pitfalls to Avoid

1. Over-testing mild hirsutism: Women with isolated mild hirsutism and regular menses rarely have clinically significant androgen disorders 1

2. Missing tumors: Rapid progression, very high testosterone (>200 ng/dL), or virilization signs demand immediate imaging even if other features suggest benign causes 1, 2

3. Inadequate contraception with antiandrogens: Never use antiandrogens as monotherapy in women of reproductive potential without reliable contraception 1

4. Premature treatment changes: Resist changing therapy before 6 months, as improvement is gradual 1

5. Ignoring PCOS screening: Even with normal testosterone, assess for metabolic complications (insulin resistance, dyslipidemia, cardiovascular risk) if PCOS features are present 1